Gunderson Dettmer represented client Carbon Biosciences, a developer of novel parvovirus-derived gene therapies, in its emergence from stealth mode and the closing of a $38 million in Series A financing led by Agent Capital. The biotech company’s novel platform addresses key challenges with AAV and non-viral based therapies. Carbon will use its new capital to advance the development of its programs for genetic diseases and push its cystic fibrosis candidate into the clinic.

In the announcement of the de-stealth and transaction, President and CEO of Carbon Biosciences Joel Schneider, Ph.D., said “Carbon’s platform has the potential to expand the role of gene therapy in treating some of the world’s most devastating and difficult to treat diseases. Our vision is to enable a new generation of genetic medicines with differentiated vectors that have the potential to address the immunological, targeting and payload limitations inherent in current viral and non-viral delivery technologies. As the first jointly funded program launched under a collaborative agreement between the Cystic Fibrosis Foundation and Longwood Fund, we are motivated by the potential impact our research may have in significantly improving care for cystic fibrosis patients.”

The Gunderson team representing Carbon Biosciences was led by Tim Ehrlich and included Tim Kulis, Aditya Perakath, Morgan Clarke, Joel Diamond, Kelvin Chan and Julie Bateman.

Companies:
Carbon Biosciences